← Leaderboards
Bahaa Elgendy
St. Louis College Of Pharmacy
$3,011,885
Attributed
$7,349,842
Total exposure
5
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.9M · FY2020–25$5M$3.8M$2.5M$1.3M$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,349,842 · 5
By mechanism
R01$3,072,798 · 2
RF1$2,262,938 · 1
R61$1,587,553 · 1
R21$426,553 · 1
Top collaborators
- Lamees Hegazy5 shared
- Kristine Griffett4 shared
- Ajay K. Jain2 shared
- Gwendalyn J Randolph2 shared
- Brad Wayne Warner2 shared
- Thomas P Burris1 shared
- Simon Haroutounian1 shared
Most similar at St. Louis College Of Pharmacy
Same institution · by research overlap
- Lamees Hegazy$1,729,009
Others in their field
Other Emerging Leaders on “Design”
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- John E West · University Of Texas At Austin$113,883,001
- Peter K Fritschel · California Institute Of Technology$78,820,000
- Kevin Urdahl · Seattle Children'S Hospital$72,239,698
- Marlene Ann Cooper · Harvard University D/B/A Harvard School Of Public Health$71,439,892
Research focus
DesignCellsAlzheimer&AposAgonistMouse ModelLigandsAffectProtein IsoformsTranscription FactorBindingMetabolismIn VivoBiochemicalIn VitroReceptorStructureNuclear ReceptorsMediatingAmericanMechanicsBiologyChronic Painful ConditionChronicAddiction Liability
Grant awards (9)
Developing Chemical Probes for Inflammatory Pain$615,993
R01 · FY2025 · NS · contact PI
Intestinally restricted LXR agonism in ameliorating liver failure in short gut syndrome$590,587
R01 · FY2025 · DK
Development of CNS-Active 5-HT3R Antagonists for the Treatment of Neuropathic Pain$1,587,553
R61 · FY2024 · NS · contact PI
Intestinally restricted LXR agonism in ameliorating liver failure in short gut syndrome$604,462
R01 · FY2024 · DK
Exercise Mimetics for Dementia and Alzheimer's Disease$2,262,938
RF1 · FY2023 · AG
Developing Chemical Probes for Inflammatory Pain$476,822
R01 · FY2023 · NS · contact PI
Developing Chemical Probes for Inflammatory Pain$148,183
R01 · FY2023 · NS · contact PI
Developing Chemical Probes for Inflammatory Pain$636,751
R01 · FY2022 · NS · contact PI
Development of Novel ERRa Selective Agonists as Chemical Probes for the Potential Treatment of Alzheimer's Disease$426,553
R21 · FY2020 · AG · contact PI